| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Common Stock | Options Exercise | $0 | +11.8K | +28.53% | $0.00 | 53K | Jan 1, 2024 | Direct | F1 |
| transaction | BSX | Common Stock | Tax liability | -$311K | -5.38K | -10.14% | $57.81 | 47.7K | Jan 1, 2024 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Performance Share Units | Options Exercise | $0 | -11.8K | -100% | $0.00* | 0 | Jan 1, 2024 | Common Stock | 11.8K | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. |
| F2 | Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. |